Abstract:Objective: To analyze the clinical efficacy of basic fibroblast growth factor (bFGF) eye drops combined with fluorometholone eye drops in the treatment of severe dry eye syndrome with corneal injury. Method: A retrospective analysis was conducted on 104 patients (104 eyes) with severe dry eye syndrome and corneal injury after cataract phacoemulsification surgery admitted to the hospital from January 2022 to December 2024. According to different treatment plans for dry eye syndrome, they were divided into two groups: a control group of 50 eyes were treated with conventional artificial tears and fluorometholone eye drops; 54 eyes in the observation group were treated with conventional artificial tears+bFGF eye drops combined with fluorometholone eye drops for a course of 8 weeks. The ocular surface disease index (OSDI), tear film rupture time (BUT), corneal fluorescein sodium staining (FL) score, and tear inflammatory factors [interleukin-1 β (IL-1 β) and interleukin-18 (IL-18)] were compared between the two groups before and 4 and 8 weeks after treatment. Statistics on the occurrence of adverse reactions in the eyes of two groups during the treatment period. Result: After 4 and 8 weeks of treatment, the OSDI, FL, and IL-1 β and IL-18 in tears of both groups were lower than before treatment, and the BUT was higher than before treatment (all P<0.001). The OSDI, FL, and IL-1 β and IL-18 in tears of the observation group were lower than those of the control group, and the BUT was higher than that of the control group (all P<0.001). During the follow-up period of treatment, there was no statistical significant difference in the incidence of eye adverse reactions between the two groups of patients (P>0.05).Conclusion: The combination of bFGF eye drops and fluorometholone eye drops can effectively improve dry eye symptoms in patients with severe dry eye syndrome and corneal injury, improve tear film stability and corneal injury repair, and inhibit ocular surface inflammation, with acceptable safety.
